Home > Rheumatology > ACR 2020 > Late-Breaking News > Autotaxin inhibitor successful in the first trial in diffuse cutaneous systemic sclerosis

Autotaxin inhibitor successful in the first trial in diffuse cutaneous systemic sclerosis

Presented By
Prof. Dinesh Khanna, University of Michigan Scleroderma Program, USA
Conference
ACR 2020
Trial
Phase 2, NOVESA
Autotaxin inhibition is a fascinating novel treatment approach for systemic sclerosis patients, where there are no specific treatment options. Ziritaxestat proved to be efficacious and tolerable in a phase 2 trial. Vasculopathy, inflammation, and fibrosis form a specific triad of features found in systemic sclerosis (SSc), a disease with a high unmet need for novel treatments. While the pathogenesis of SSc remains uncertain, lysophosphatidic acid (LPA) is a well-known pro-fibrotic and pro-inflammatory lysophospholipid that has been implicated in the pathogenesis of SSc. LPA is generated at sites of inflammation by autotaxin-mediated hydrolysis of lysophosphatidylcholine and other lysophospholipids. Ziritaxestat is an autotaxin inhibitor with a novel mechanism of action that could be promising for modulating the skin pathology of SSc and as such might be able to fill the current treatment gap. The current randomised, double-blind, placebo-controlled phase 2...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on